<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="24326">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02790073</url>
  </required_header>
  <id_info>
    <org_study_id>SNFCT2015_04</org_study_id>
    <nct_id>NCT02790073</nct_id>
  </id_info>
  <brief_title>Phase 2 Study With SNF472 in Calciphylaxis Patients</brief_title>
  <official_title>Phase 2 Open Label Single Arm Repeat Dose Study to Assess the Effect of SNF472 on Wound Healing in Uraemic Calciphylaxis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoris Sanifit</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoris Sanifit</source>
  <brief_summary>
    <textblock>
      To evaluate the effect of SNF472 on top of standard of care on promoting wound healing and
      other parameters of therapeutic response in haemodialysis patients with calciphylaxis
      (calcific uraemic arteriolopathy, CUA).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression of 3 lesions, including primary lesion by collecting images of lesions</measure>
    <time_frame>During 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of lesion score using Bates-Jensen wound assessment tool</measure>
    <time_frame>During 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of wound infection (absence or presence)</measure>
    <time_frame>During 12 weeks</time_frame>
    <description>For the primary and the secondary lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of systemic infection (absence or presence)</measure>
    <time_frame>During 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical treatment of the wound</measure>
    <time_frame>During 12 weeks</time_frame>
    <description>Collection of surgical treatments performed of the wound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalisation defined as being admitted for &gt;24 hours</measure>
    <time_frame>During 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Course of the secondary lesions defined clinically as for the primary lesion</measure>
    <time_frame>During 12 weeks</time_frame>
    <description>By collecting images of the secondary lesions, assessing the progression of the lesions during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain according to Pain Visual Analogue Scale (VAS)</measure>
    <time_frame>During 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in dose and type of pain medication</measure>
    <time_frame>During 12 weeks</time_frame>
    <description>Documenting name, dose and number of pills</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess quality of life (QOL) based on wound QOL score</measure>
    <time_frame>During 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>During 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Calciphylaxis</condition>
  <condition>Calcific Uremic Arteriolopathy</condition>
  <arm_group>
    <arm_group_label>SNF472</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>SNF472 for calciphylaxis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SNF472</intervention_name>
    <description>SNF472 for calciphylaxis</description>
    <arm_group_label>SNF472</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with newly diagnosed CUA (diagnosed within 5 weeks of study start)

          2. Patients who signed the written informed consent to participate in this clinical
             trial (prior to any clinical trial-related procedures being performed), after reading
             the Patient Information Sheet and Informed Consent Form (ICF), and who had the
             opportunity to discuss the clinical trial with the Investigator or designee

          3. Males or females aged â‰¥18

          4. Patients on maintenance haemodialysis

          5. Patients with at least a minimum level of pain on VAS scale or on pain-killers
             stronger than NSAIDs

          6. Females of child-bearing potential should use a highly effective contraceptive
             measure throughout the study AND have a negative serum pregnancy test at entry. Male
             patients having sexual relationship in which pregnancy can occur should take adequate
             contraceptive precautions (wear a condom)

        Exclusion Criteria:

          1. Body weight above 150 kg

          2. BMI &gt;35 and central(abdominal) ulcers

          3. History of bisphosphonate treatment within 12 months before entering into the study

          4. Severely ill patients without reasonable expectation of survival for &gt; 6 months
             according to the treating physician

          5. Patients with scheduled parathyroidectomy during the run-in or study period

          6. Female patients who are either intending to get pregnant or are undergoing treatment
             to get pregnant, as well as breast-feeding females

          7. Participation in another clinical trial with an experimental drug within 90 days
             prior the inclusion

          8. Any psychological, emotional problems, any disorders or resultant therapy that is
             likely to invalidate informed consent, or limit the ability of the patient to comply
             with the Clinical Trial Protocol requirements

          9. Patients who, in the opinion of the Investigator, are considered unsuitable for any
             other reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Brandenburg</last_name>
    <role>Principal Investigator</role>
    <affiliation>RWTH Aachen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ana-Zeralda Canals</last_name>
    <phone>+34 971439925</phone>
    <email>ana-zeralda.canals@sanifit.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fresenius Medical Services</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn Maloney</last_name>
      <phone>781-699-2714</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Davita Clinical Research</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meredith Schreier</last_name>
      <phone>612-852-7016</phone>
      <email>Meredith.Schreier@davita.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Connaire, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>RWTH Aachen Univeristy</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Coburg Kuratorium</name>
      <address>
        <city>Coburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vicens Torregrosa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salford Royal Hospital</name>
      <address>
        <city>Salford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Smeeta Sinha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.gov/ct2/info/fdalinks</url>
    <description>USA FDA resources</description>
  </link>
  <link>
    <url>http://rarediseases.info.nih.gov/gard/5980/calciphylaxis/resources/1</url>
    <description>Genetic and Rare Diseases Information Center resources: Calciphylaxis</description>
  </link>
  <link>
    <url>http://www.sanifit.com</url>
    <description>Drug Information available for: SNF472</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 22, 2017</lastchanged_date>
  <firstreceived_date>May 25, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Calciphylaxis</keyword>
  <keyword>Calcific Uremic Arteriolopathy</keyword>
  <keyword>Dialysis</keyword>
  <keyword>End Stage Renal Disease</keyword>
  <keyword>Rare disease (ORPHA280062)</keyword>
  <keyword>Calcification</keyword>
  <keyword>Calcium Metabolism Disorders</keyword>
  <keyword>Calcinosis</keyword>
  <keyword>Metabolic Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calciphylaxis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
